Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.89, $0.03 better than the analyst estimate of $3.86. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.42 billion.

Guidance:
Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.